Corbion Lowers 2026 Margin Guidance Despite 8.5% Growth in Q2
Corbion released its half-year results marked by a contrast between the rebound in the second quarter (organic growth of +8.5%) and profitability significantly down over the entire semester. Adjusted EBITDA margin fell to 14.1%, compared to 16.5% a year earlier, and the group lowered its margin target for the year, from approximately 17% to above 16%, due to costs it considers still unfavorable in the second half.
A Mixed First Half, but Acceleration in the Second Quarter
First half 2026 revenue stood at €631.1 million, down 2.2% compared to the same period in 2025 (€645.6 million). This performance masks a contrasting dynamic: cumulative organic growth over six months reached +2.1%, but accelerated significantly in the second quarter, to +8.5%, supported by volume/mix growth of +10.7% in the quarter. Management notes, however, that this acceleration is partly due to an expected calendar effect, and attributes the semester's volume/mix progression (+4.0%) to the "resilience" of its portfolio and the execution of its teams, in the two main divisions: Functional Ingredients & Solutions and Health & Nutrition.
Adjusted EBITDA for the semester reached €88.8 million, compared to €106.6 million a year earlier, a total decline of 16.7% (organic decline of 8.0%). In the second quarter alone, organic adjusted EBITDA growth reached +4.2%, compared to an organic decline of 8.0% over the entire semester.
Profitability Hindered by Costs and Prices
Adjusted EBITDA margin contracted to 14.1% in the first half of 2026, compared to 16.5% in the previous year, marking an erosion of 2.4 percentage points. Management noted that the second quarter margin improved sequentially from the first, to 15.1%, but remains below the second quarter of 2025 (16.5%). Corbion warns that the second half will remain exposed to "significant cost-related challenges," while anticipating a margin increase compared to the first semester.
On the pricing front, the group recorded an overall price decline of 1.9% over the semester, with varying conditions depending on segments. In Functional Ingredients & Solutions, the price decline of 0.6% is largely attributable to lactic acid prices supplied to the PLA joint venture, while prices for the rest of the business remained above the prior year level. In Health & Nutrition, the price decline of 6.1% was driven by lower omega-3 oil prices, a segment where management anticipates a "substantial" increase from the third quarter 2026 onwards.
Revised Guidance Downward, Growth and Cash-Flow Confirmed
Corbion lowered its EBITDA margin target for the 2026 fiscal year, from approximately 17% to above 16%, while confirming its objectives for organic growth (+3% to +6%) and free cash-flow (€85 to €90 million). Chief Executive Officer Olivier Rigaud attributed this revision to the persistence of macroeconomic uncertainty and the "unforeseen" impacts of the Middle East war on raw material prices, freight costs and energy expenses. The group nonetheless continues to anticipate an increase in margins in the second half, supported by cost reduction measures, price increases and continued volume/mix development.
